RasCase®

Rasburicase Injection
(r-DNA origin) 1.5mg

Sayre Therapeutics offers clinicians an FDA approved option to manage Tumor Lysis Syndrome.

  • Indication: FDA approved for the prevention and treatment of Tumor Lysis Syndrome (TLS).
  • Formulation: Rasburicase Injection 1.5 mg for Intra venous administration.
  • RasCase®is
    • An offering for haematologists and medical oncologists to manage TLS.
    • Backed by robust evidence from International trials and an Indian Phase III trial with 100 patients published in Indian Journal of Cancer.
  • What is TLS ?
    • A condition in which tumour cells release their content into bloodstream either spontaneously or in response to chemotherapy.
    • Most common in rapidly growing haematologic malignancies but has been reported in virtually every cancer type.
    • Prevention is the key as management can be challenging.

“Rascase® results are terrific, you can see the uric acid levels decreasing from the first dose” Medical Oncologist, Delhi

For more information regarding RasCase®, please contact your local sales representative or email us at info@sayretherapeutics.com